SCHEMBL6490865

SCHEMBL6490865

CCOC(=O)CCCCCOc1ccc(NC(C)=O)c([N+](=O)[O-])c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.57
MAPT P10636 9/20 0.53
KDM4E B2RXH2 1/20 0.53
MAPK1 P28482 4/20 0.52
LMNA P02545 4/20 0.52
RAB9A P51151 7/20 0.50
SMN1; SMN2 Q16637 7/20 0.50
NPC1 O15118 6/20 0.50
POLB P06746 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
PKM P14618 1/20 0.50
CYP1A2 P05177 3/20 0.49
CYP2C9 P11712 2/20 0.49
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
NPSR1 Q6W5P4 3/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
GALR2 O43603 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490315 0.96 KMT2A (0.60) KMT2AMAPTKDM4EMAPK1LMNA
SCHEMBL16742373 0.87 MAPT (0.60) KMT2AMAPTMAPK1LMNARAB9A
SCHEMBL11659558 0.85 MAPT (0.64) KMT2AMAPTMAPK1LMNARAB9A
SCHEMBL18109932 0.84 KMT2A (0.52) KMT2AMAPTMAPK1LMNARAB9A
SCHEMBL18155122 0.84 ALDH1A1 (0.52) MAPTKDM4ELMNAL3MBTL1CYP1A2
SCHEMBL11406573 0.84 KMT2A (0.59) KMT2AMAPTMAPK1LMNARAB9A
SCHEMBL11295618 0.83 MAPT (0.68) KMT2AMAPTMAPK1LMNARAB9A
SCHEMBL6500650 0.82 MAPT (0.52) KMT2AMAPTKDM4EMAPK1LMNA
SCHEMBL11631142 0.82 KMT2A (0.58) KMT2AMAPTMAPK1LMNARAB9A
SCHEMBL11842489 0.82 MAPT (0.65) KMT2AMAPTKDM4EMAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD KMT2A 561/4885MAPT 3168/4885KDM4E 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.